Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12018411 | 0.83 | CYP1A2 (0.42) | ALOX5OPRM1OPRD1OPRK1ADRA1B | |
| SCHEMBL4675824 | 0.83 | ALOX5 (0.40) | ALOX5OPRM1OPRD1OPRK1CHRM5 | |
| SCHEMBL20900599 | 0.83 | CYP1A2 (0.42) | ALOX5OPRM1OPRD1OPRK1ADRA1B | |
| SCHEMBL16559079 | 0.83 | CYP1A2 (0.42) | ALOX5OPRM1OPRD1OPRK1ADRA1B | |
| SCHEMBL130374 | 0.83 | ALOX5 (0.36) | ALOX5OPRM1OPRD1OPRK1ADRA1B | |
| SCHEMBL9016981 | 0.81 | ALOX5 (0.39) | ALOX5OPRM1OPRD1OPRK1CHRM5 | |
| SCHEMBL9016983 | 0.81 | ALOX5 (0.39) | ALOX5OPRM1OPRD1OPRK1CHRM5 | |
| SCHEMBL20611465 | 0.79 | OPRM1 (0.41) | ALOX5OPRM1OPRD1OPRK1ADRA1B | |
| SCHEMBL8040461 | 0.79 | CYP1A2 (0.39) | ALOX5OPRM1OPRD1OPRK1ADRA1B | |
| SCHEMBL14593329 | 0.79 | OPRM1 (0.45) | ALOX5OPRM1OPRD1OPRK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975019-A1 | RUTHENIUM CATALYZED HYDROAMINOMETHYLATION | Evonik Degussa GmbH (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-7220884-B2 | Hydroaminomethylation of olefins | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220884-B2 | Hydroaminomethylation of olefins | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220884-B2 | Hydroaminomethylation of olefins | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1713757-A2 | HYDROAMINOMETHYLATION OF OLEFINS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050215825-A1 | Hydroaminomethylation of olefins | UNION CARBIDE CORPORATION | 2005-09-29 | — | — | US | disclosed |
| WO-2005077884-A2 | HYDROAMINOMETHYLATION OF OLEFINS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| EP-0138750-B1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED BENZIMIDAZOLES | CIBA-GEIGY AG (CH) | 1987-09-09 | — | — | EP | disclosed |
| EP-0138750-A1 | Process for the production of substituted benzimidazoles | CIBA-GEIGY AG (CH) | 1985-04-24 | — | — | EP | disclosed |
| US-3947458-A | RHODIUM CATALYST, REACTING NITROGEN COMPOUND, OLEFIN, CARBON MONOXIDE, WATER | MONSANTO COMPANY (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215825-A1 | Hydroaminomethylation of olefins | HRH2, HRH4, HRH1 | ALOX5 73/4885OPRM1 33/4885OPRD1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.